Mitchell Austin Rudy Acquires 11,659 Shares of Bonk (NASDAQ:BNKK) Stock

Bonk, Inc. (NASDAQ:BNKK) Director Mitchell Austin Rudy purchased 11,659 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was bought at an average cost of $1.47 per share, with a total value of $17,138.73. Following the acquisition, the director owned 85,000 shares of the company’s stock, valued at approximately $124,950. The trade was a 15.90% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Mitchell Austin Rudy also recently made the following trade(s):

• On Monday, June 22nd, Mitchell Austin Rudy acquired 7,500 shares of Bonk stock. The shares were bought at an average cost of $1.56 per share, for a total transaction of $11,700.00.
• On Tuesday, June 16th, Mitchell Austin Rudy bought 2,500 shares of Bonk stock. The stock was purchased at an average cost of $1.32 per share, for a total transaction of $3,300.00.
• On Wednesday, June 10th, Mitchell Austin Rudy bought 12,000 shares of Bonk stock. The stock was purchased at an average price of $1.37 per share, with a total value of $16,440.00.
• On Thursday, April 9th, Mitchell Austin Rudy purchased 31,055 shares of Bonk stock. The shares were purchased at an average cost of $2.82 per share, with a total value of $87,575.10.

Bonk Stock Performance

Bonk stock opened at $1.31 on Thursday. The business’s 50-day simple moving average is $1.81 and its two-hundred day simple moving average is $2.76. The company has a market cap of $10.48 million, a PE ratio of -0.28 and a beta of 1.89. Bonk, Inc. has a fifty-two week low of $1.25 and a fifty-two week high of $46.90.

Bonk (NASDAQ:BNKK) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) EPS for the quarter. The business had revenue of $0.79 million for the quarter. Bonk had a negative net margin of 838.37% and a negative return on equity of 148.62%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on BNKK shares. Weiss Ratings downgraded Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. Wall Street Zen raised Bonk from a “sell” rating to a “hold” rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Bonk

Several large investors have recently made changes to their positions in BNKK. State Street Corp purchased a new stake in Bonk during the fourth quarter worth $33,000. Steward Partners Investment Advisory LLC purchased a new position in Bonk in the fourth quarter valued at $37,000. Jane Street Group LLC acquired a new position in shares of Bonk in the fourth quarter worth about $96,000. Finally, Geode Capital Management LLC acquired a new position in shares of Bonk in the fourth quarter worth about $128,000. 12.55% of the stock is currently owned by institutional investors and hedge funds.

Bonk Company Profile

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.